<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:media="http://search.yahoo.com/mrss/"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Therapeutics &#8211; USA NEWS LIVE</title>
	<atom:link href="https://bloggingthree.soflytech.com/tag/therapeutics/feed/" rel="self" type="application/rss+xml" />
	<link>https://bloggingthree.soflytech.com</link>
	<description>All About USA NEWS</description>
	<lastBuildDate>Tue, 12 Nov 2024 22:19:19 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.4</generator>

<image>
	<url>https://bloggingthree.soflytech.com/wp-content/uploads/2024/04/cropped-THE-USA1-e1713184454543-1-32x32.png</url>
	<title>Therapeutics &#8211; USA NEWS LIVE</title>
	<link>https://bloggingthree.soflytech.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Bay Area-based 23andMe to chop 40% of workforce, shut down therapeutics division &#8211; The Mercury News</title>
		<link>https://bloggingthree.soflytech.com/2024/11/bay-area-based-23andme-to-chop-40-of-workforce-shut-down-therapeutics-division-the-mercury-news/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Tue, 12 Nov 2024 22:19:18 +0000</pubDate>
				<category><![CDATA[Technology]]></category>
		<category><![CDATA[23andMe]]></category>
		<category><![CDATA[Areabased]]></category>
		<category><![CDATA[Bay]]></category>
		<category><![CDATA[cut]]></category>
		<category><![CDATA[division]]></category>
		<category><![CDATA[Mercury]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[shut]]></category>
		<category><![CDATA[Therapeutics]]></category>
		<category><![CDATA[workforce]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=19018</guid>

					<description><![CDATA[NEW YORK &#8211; 23andMe is shedding 40% of its workforce, greater than 200 employees, and shutting down its therapeutics division because the struggling genetic testing company tries to chop costs. The latest restructuring efforts were announced by 23andMe on Monday. The company said it plans to finish ongoing clinical trials &#8220;as quickly as possible&#8221; &#8211; [&#8230;]]]></description>
										<content:encoded><![CDATA[<p><img decoding="async" src="https://www.mercurynews.com/wp-content/uploads/2024/11/AP24317603053450-2.jpg?w=1400px&amp;strip=all" /></p>
<div>
<p>NEW YORK &#8211; 23andMe is shedding 40% of its workforce, greater than 200 employees, and shutting down its therapeutics division because the struggling genetic testing company tries to chop costs.</p>
<p>The latest restructuring efforts were announced by 23andMe on Monday. The company said it plans to finish ongoing clinical trials &#8220;as quickly as possible&#8221; &#8211; and is currently evaluating &#8220;strategic alternatives&#8221; for assets related to its drug development and research programs, which include studies of potential cancer treatments.</p>
<p>In a prepared statement, Anne Wojcicki, CEO and co-founder of 23andMe, said the corporate is &#8220;taking these difficult but necessary actions&#8221; because it focuses on &#8220;the long-term success of our core consumer businesses and our research partnerships.&#8221;</p>
<p><strong>RELATED: Southwest Air offers buyouts at 18 airports and headquarters</strong></p>
<p>The restructuring comes at a time of turmoil at South San Francisco-based 23andMe, which has recently led to a high-profile data breach, several previous rounds of layoffs and steep losses which have sent the corporate&#39;s stock plummeting in recent times.</p>
<p>Back in September, all of 23andMe&#39;s independent directors also resigned from the board &#8211; a rare move that followed protracted negotiations with Wojcicki, who had sought to take the corporate private. The seven resigning directors said that they had not yet received an appropriate transaction proposal from the chief executive, citing a &#8220;clear&#8221; disagreement over the long run of 23andMe.</p>
<p>After leaving Wojcicki as sole board member for greater than a month, 23andMe announced it had appointed three latest independent directors in late October.</p>
<p>23andMe went public in 2021 and has struggled to search out a profitable business model ever since — especially since most buyers of its saliva-based testing kits only must make a one-time purchase. The company posted a net lack of $667 million in its most up-to-date fiscal 12 months, greater than double the $312 million loss the previous 12 months.</p>
<p><strong>RELATED: The Bay Area is losing tons of more tech jobs as region cuts proceed</strong></p>
<p>23andMe posted one other loss in its quarterly results reported Tuesday, although with smaller losses than in previous quarters. The company reported a net lack of $59.1 million for the second quarter of fiscal 2025, in comparison with a lack of $75.3 million the identical 12 months before.</p>
<p>However, second-quarter revenue totaled $44.1 million &#8211; down from $50 million a 12 months ago. The company cited lower sales of testing kits and telemedicine orders and a decline in research revenue, but said that was partially offset by growth in member services.</p>
<p>23andMe expects the job cuts and other restructuring measures announced Monday will reduce operating costs and save the corporate greater than $35 million annually. 23andMe also expects to incur costs of as much as $12 million, primarily related to one-time severance and other termination-related costs.</p>
<p>23andMe ended the quarter with money and money equivalents of $127 million, in comparison with $216 million as of March 31, 2024.</p>
<p>Last month, 23andMe accomplished a 1-for-20 reverse stock split. By midday Tuesday, shares were down nearly 4%, trading at around $4.43.</p>
</p></div>
<p><em>image credit : www.mercurynews.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://www.mercurynews.com/wp-content/uploads/2024/11/AP24317603053450-2.jpg?w=1024&#038;h=800" medium="image"></media:content>
	</item>
		<item>
		<title>Healthy Yields: The race for weight reduction drugs heats up with pill data from Viking Therapeutics and AstraZeneca</title>
		<link>https://bloggingthree.soflytech.com/2024/11/healthy-yields-the-race-for-weight-reduction-drugs-heats-up-with-pill-data-from-viking-therapeutics-and-astrazeneca/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Fri, 08 Nov 2024 21:43:38 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Data]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[healthy]]></category>
		<category><![CDATA[heats]]></category>
		<category><![CDATA[loss]]></category>
		<category><![CDATA[pill]]></category>
		<category><![CDATA[race]]></category>
		<category><![CDATA[Therapeutics]]></category>
		<category><![CDATA[Viking]]></category>
		<category><![CDATA[weight]]></category>
		<category><![CDATA[Yields]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=18803</guid>

					<description><![CDATA[Happy Friday! Buried on this week&#39;s election news was recent data from drugmakers racing to get into the booming weight-loss drug market. Pharmaceutical giant AstraZeneca and biotech corporations Viking Therapeutics were amongst the businesses presenting encouraging data on their obesity pills and other treatments on the ObesityWeek conference in San Antonio, Texas, in recent days. [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div id="SpecialReportArticle-ArticleBody-6" data-module="ArticleBody" data-test="articleBody-2" data-analytics="SpecialReportArticle-articleBody-6-2"><span class="HighlightShare-hidden" style="top:0;left:0"></span></p>
<div class="group">
<p>Happy Friday! Buried on this week&#39;s election news was recent data from drugmakers racing to get into the booming weight-loss drug market. </p>
<p>Pharmaceutical giant <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="SpecialReportArticle-QuoteInBody-2">AstraZeneca<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>    and biotech corporations <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="SpecialReportArticle-QuoteInBody-3">Viking Therapeutics<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>    were amongst the businesses presenting encouraging data on their obesity pills and other treatments on the ObesityWeek conference in San Antonio, Texas, in recent days. </p>
<p>Wall Street expects the brand new wave of obesity growth to be driven by pills that might offer more convenience and potentially fewer unwanted side effects, which may lead patients to take the drugs for longer. Analysts expect the marketplace for weight reduction drugs to be value greater than $100 billion by the tip of the last decade as more treatments come to market and help meet demand created by existing ones Injections occur <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="SpecialReportArticle-QuoteInBody-5">Novo Nordisk<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>    And <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="SpecialReportArticle-QuoteInBody-6">Eli Lilly<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>    still struggling to maintain up. </p>
<p>Here&#39;s what a few of the data on the pills looked like. </p>
<p>People who took the very best dose of the every day Viking pill lost a median of 6.8% of their body weight after 28 days in comparison with those that received a placebo, in line with results of an early study in 92 people. </p>
<p>That beat investors&#39; expectations of a 5% to six% weight reduction compared with a placebo, William Blair analyst Andy Hsieh said in a note Monday. That bar was set by an experimental pill from Novo Nordisk that showed a 5% weight reduction in 4 weeks, he noted. </p>
<p>Hsieh also said Viking&#39;s pill had an &#8220;extremely benign tolerability profile,&#8221; referring to how well patients tolerated the drug. Six of nine participants who took the very best dose of the drug experienced mild nausea, while just one experienced vomiting.</p>
<p>This could potentially be a bonus over existing anti-obesity injections, which may cause gastrointestinal unwanted side effects so unpleasant that they prompt some patients to stop treatment. </p>
<p>Still, some analysts questioned whether Viking could capture a big share of the competitive weight-loss drug market, particularly raising concerns about its ability to supply enough drugs as a small company. </p>
<p>&#8220;We&#39;re not saying manufacturing is impossible for Viking, but we think it will be costly because the capital needs and expertise go beyond what Lilly and Novo currently have,&#8221; said James Shin, an analyst on the Deutsche Bank said in an announcement on Monday. </p>
<p>But Hsieh said he believes Viking offers &#8220;a unique set of attractive properties from the perspective of big pharma.&#8221; There has already been speculation in regards to the possibility that Viking could possibly be acquired by a serious pharmaceutical company. </p>
<p>In addition to the pill, Viking can be developing a weight reduction injection and other treatments. </p>
</div>
<div class="group">
<p>Meanwhile, AstraZeneca said its experimental obesity pill was well tolerated in patients with type 2 diabetes in an early trial, presenting data from multiple trials on three recent treatments in the course of the conference. </p>
<p>After AstraZeneca announced last 12 months that it will license Chinese drugmaker Eccogene&#39;s once-daily pill, it said it believed the pill could cause fewer unwanted side effects than injectable treatments from Novo Nordisk and Eli Lilly. </p>
<p>Patients with diabetes lost 5.8% of their body weight inside 4 weeks of treatment with the AstraZeneca pill. </p>
<p>Some analysts said it was difficult to match the information with other weight-loss drugs because AstraZeneca&#39;s trial was small and tested on diabetics relatively than those with obesity. Still, AstraZeneca believes its pill is different from other therapies in development and in the marketplace, especially given how well it&#8217;s tolerated by patients. </p>
<p>You can send suggestions, suggestions, story ideas and data to Annika at <a href="http://nbcuni.com/?__source=newsletter%7Chealthyreturns" target="_blank" rel="noopener">annikakim.constantino@nbcuni.com</a>.</p>
</div>
<h2 class="ArticleBody-subtitle"><a id="headline0"></a>This is how Americans voted on abortion access</h2>
<div class="group">
<p><strong>This is how Americans voted on abortion access</strong></p>
<p>Americans in 10 states voted this week on whether to enshrine or expand access to abortion, greater than two years after Roe v. Wade was overturned by the US Supreme Court. </p>
<p>Abortion access was a hot topic during this 12 months&#39;s presidential campaign, particularly amongst female voters. President-elect Donald Trump recently said he believes the difficulty ought to be left to the states, but has previously expressed support for various proposals for a nationwide ban.<strong> </strong></p>
<p>Ballots are still being counted across the country, but here&#39;s how Americans voted on abortion, in line with NBC News forecasts: </p>
<p><strong>Arizona: Passed</strong></p>
<p>Arizona voters passed Proposition 139, which establishes a right to abortion within the state before the fetus becomes viable at about 24 weeks. </p>
<p>According to NBC News, the measure passed with 61.2% of the vote, while 38.8% of Arizonans voted against it. So far, about 74% of the expected votes have been counted. </p>
<p><strong>Colorado: Passed</strong></p>
<p>Colorado voters passed Amendment 79, which enshrines the best to abortion within the state structure. It also lifted a ban that prevented public funds from getting used to finance abortions, meaning more Coloradans can get insurance coverage for the procedure.</p>
<p>According to NBC News, Amendment 79 passed with 61.9% of the vote. About 86% of the expected votes have been received.</p>
<p><strong>Florida: Failed</strong></p>
<p>Florida voters rejected Amendment 4, which might have provided a constitutional right to abortion before fetal viability or if the procedure was crucial to guard the patient&#39;s health. Abortions are currently banned within the state after the sixth week of pregnancy. </p>
<p>According to NBC News, greater than 57% of Floridians voted for the change. It needed to exceed 60% to pass. About 96% of the expected votes were counted.</p>
<p><strong>Maryland: Passed</strong></p>
<p>Maryland voters enshrined abortion access within the state&#39;s structure by passing a right to reproductive freedom, which incorporates &#8220;the ability to make and implement decisions to prevent, continue, or terminate one&#39;s pregnancy.&#8221;</p>
<p>According to NBC News, the measure passed with 74.7% of the vote. About 83% of the expected votes have been received.</p>
<p><strong>Missouri: Passed</strong></p>
<p>Missouri voters passed Amendment 3, enshrining a right to reproductive freedom within the state structure. The amendment gives residents “the right to make and carry out decisions on all matters related to reproductive health care,” including abortion. </p>
<p>According to NBC News, Amendment 3 passed with 51.7% of the vote, while 48.3% of individuals within the state voted against it. Around 99% of the expected votes were received.</p>
<p><strong>Montana: Passed</strong></p>
<p>Montana voters enshrined abortion access of their state&#39;s structure, establishing the best to &#8220;make and implement decisions about one&#39;s pregnancy.&#8221; </p>
<p>According to NBC News, the measure passed with 57.6% of the vote, while 42.4% of voters voted against it. About 96% of the expected votes were counted.</p>
<p><strong>Nebraska: Mixed</strong></p>
<p>Nebraska voters didn&#8217;t pass an amendment that might have expanded access to abortions until the fetus is viable at about 24 weeks, but they did pass a measure that codified existing abortion restrictions within the state structure. Nebraska bans abortions after 12 weeks unless there&#8217;s a medical emergency or the pregnancy is the results of sexual assault or incest. </p>
<p>According to NBC News, nearly 49% of Nebraska voters voted in favor of expanding access to abortion, while 51.4% voted against it. The amendment banning abortions after the primary trimester passed with 55.3% of the vote. About 94% of the expected votes have been received.</p>
<p><strong>Nevada: Passed</strong></p>
<p>Nevada voters passed an amendment banning abortions after the primary trimester unless medically crucial. The amendment also provides exceptions if the pregnancy is the results of incest or sexual assault.  </p>
<p>According to NBC News, the amendment passed with 64% of the vote. So far, around 92% of the expected votes have been counted.</p>
<p><strong>New York: Passed</strong> </p>
<p>New York voters passed Proposition 1, which protects access to abortion within the state structure. The proposal states that folks mustn&#8217;t be denied rights based on their gender, including “sexual orientation, gender identity, gender expression, pregnancy, pregnancy outcome, and reproductive health care and autonomy.” </p>
<p>According to NBC News, nearly 62% of New York voters voted in favor of the proposal, while 38.1% voted against it. About 88% of the expected votes have been received.</p>
<p><strong>South Dakota: Failed</strong></p>
<p>South Dakota voters didn&#8217;t approve Amendment G, which might have enshrined a right to abortion within the state structure. All abortions are banned within the state unless they&#8217;re medically crucial to save lots of the patient&#39;s life. </p>
<p>According to NBC News, greater than 41% of voters within the state voted in favor of the change, while 58.6% of individuals voted against it. Around 99% of the expected votes were counted.</p>
<p>Feel free to send suggestions, suggestions, story ideas and data to Ashley at ashley.caroot@nbcuni.com.</p>
</div>
</div>
<p><em>image credit : www.cnbc.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://image.cnbcfm.com/api/v1/image/107200974-1677600992263-gettyimages-1351638407-16.jpeg?v=1731086406&#038;w=1920&#038;h=1080" medium="image"></media:content>
	</item>
		<item>
		<title>Health &#124; FDA rejects approval of MDMA capsules from San Jose-based Lykos Therapeutics</title>
		<link>https://bloggingthree.soflytech.com/2024/08/health-fda-rejects-approval-of-mdma-capsules-from-san-jose-based-lykos-therapeutics/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Fri, 09 Aug 2024 22:45:38 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[capsules]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Josebased]]></category>
		<category><![CDATA[Lykos]]></category>
		<category><![CDATA[MDMA]]></category>
		<category><![CDATA[rejects]]></category>
		<category><![CDATA[San]]></category>
		<category><![CDATA[Therapeutics]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=11465</guid>

					<description><![CDATA[The U.S. Food and Drug Administration has rejected approval of the psychedelic drug MDMA for the treatment of PTSD, ending any prospect of the controversial mind-altering drug, also referred to as ecstasy or molly, being legally included in modern medicine. San Jose-based drugmaker Lykos Therapeutics said the FDA informed the corporate that the drug &#8220;cannot [&#8230;]]]></description>
										<content:encoded><![CDATA[<p><img decoding="async" src="https://www.mercurynews.com/wp-content/uploads/2022/01/SJM-L-MDMA-0129-4.jpg?w=1400px&amp;strip=all" /></p>
<div>
<p>The U.S. Food and Drug Administration has rejected approval of the psychedelic drug MDMA for the treatment of PTSD, ending any prospect of the controversial mind-altering drug, also referred to as ecstasy or molly, being legally included in modern medicine.</p>
<p>San Jose-based drugmaker Lykos Therapeutics said the FDA informed the corporate that the drug &#8220;cannot be approved based on the data presented to date&#8221; and requested a further, advanced-stage study that would take several years and price thousands and thousands of dollars, in keeping with the Associated Press. The drugmaker said it will ask the agency for a re-examination.</p>
<p>By rejecting the applying, the FDA sent a robust signal that it&#8217;s exercising extreme caution when evaluating using psychedelics for therapeutic purposes. The FDA is more likely to review additional applications in the approaching years.</p>
<p>In an earlier FDA review, scientists wrote that patients who received MDMA and talk therapy experienced “rapid, clinically meaningful and durable improvements in their PTSD symptoms.”</p>
<p>However, additionally they called the study &#8220;difficult to interpret&#8221; since it was hard to say whether the advance got here from the drug or the talk therapy. They also raised several safety concerns, including the cardiac risks and abuse potential of MDMA.</p>
<p>On Friday, the FDA said the brand new drug application had &#8220;significant limitations&#8221; that &#8220;prevent the agency from concluding that the drug is safe and effective for the proposed indication.&#8221;</p>
<p>Research for the prescription capsule was conducted at UC San Francisco and funded by enterprise capital—with the prospect of patents and profits. The project began many years ago in a converted three-bedroom house on Mission Street in Santa Cruz, rented by Rick Doblin and the nonprofit group Multidisciplinary Association for Psychedelic Studies (MAPS).</p>
<p>If approved, MDMA-assisted therapy can be the primary novel treatment for PTSD that happens after a violent or traumatic experience. Antidepressants are currently the one approved medications for PTSD. But fewer than 60 percent of patients reply to this approach, and only 20 to 30 percent of patients are cured, in keeping with a 2009 article within the journal Progress in Neuro-Psychopharmacology and Biological Psychiatry.</p>
<p>&#8220;MDMA allows you to access these really deep traumatic memories in a way that doesn&#39;t induce anxiety,&#8221; Jennifer Mitchell, a UCSF neuroscientist who led the study submitted to the FDA, told the Mercury News in 2022.</p>
<p>Jonathan Lubecky, 46, a retired Army sergeant who participated in clinical trials and lives in Washington, D.C., said MDMA relieved his symptoms. After a 12 months in Iraq, he suffered from severe post-traumatic stress disorder and repeatedly woke up from nightmares drenched in sweat.</p>
<p>The drug has long languished within the shadows of the counterculture. It is currently classified by the Drug Enforcement Agency as a Schedule 1 drug, like heroin, for which there&#8217;s &#8220;no currently recognized medical use and a high potential for abuse.&#8221;</p>
<p>MDMA research received the green light from the FDA in 2017 and was granted “breakthrough therapy” status, allowing experiments to speed up.</p>
<p>In rigorously controlled studies, it has shown promising effects in relieving symptoms of post-traumatic stress disorder when combined with talk therapy. It will not be a classic hallucinogen like LSD; as an alternative, it triggers feelings of intimacy, connection and euphoria.</p>
<p>In the UCSF study funded by Lykos, patients received MDMA as a part of an intensive four-month talk therapy that included greater than a dozen sessions, three of which involved taking the drug. At the top of 1 study, 86 percent of individuals within the MDMA group were higher and 71 percent now not met the standards for a PTSD diagnosis. Of those taking the placebo, 69 percent were higher and 48 percent now not met the standards for a PTSD diagnosis.</p>
<p>But FDA staff evaluation found that the study was flawed since it was not truly &#8220;blinded.&#8221; Participants and therapists could work out who was receiving MDMA and who was receiving a placebo.</p>
<p>If the product had been approved, Lykos would have had exclusive marketing rights for five years. Under the leadership of CEO Amy Emerson, who previously worked at pharmaceutical giants Novartis and Chiron, the corporate raised around $150 million and grew to over 120 employees.</p>
<p>&#8220;The FDA&#39;s request for another study is deeply disappointing,&#8221; Emerson said in an announcement Friday. &#8220;We are heartbroken for the millions of military veterans, first responders, victims of sexual and domestic abuse, and countless others who suffer from PTSD and may now face additional years without access to new treatment options.&#8221;</p>
<p>In the approaching years, more psychedelics are expected to be reviewed by the FDA for therapeutic purposes.</p>
</p>
<p>Originally published: <time datetime="2024-08-09 15:18:58">August 9, 2024 at 3:18 pm</time></p>
</div>
<p><em>image credit : www.mercurynews.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://www.mercurynews.com/wp-content/uploads/2022/01/SJM-L-MDMA-0129-4.jpg?w=1024&#038;h=724" medium="image"></media:content>
	</item>
		<item>
		<title>Viking Therapeutics shares rise 16% after the pharmaceutical company moves its weight-loss injection into late-stage testing</title>
		<link>https://bloggingthree.soflytech.com/2024/07/viking-therapeutics-shares-rise-16-after-the-pharmaceutical-company-moves-its-weight-loss-injection-into-late-stage-testing/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Thu, 25 Jul 2024 13:34:34 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[injection]]></category>
		<category><![CDATA[latestage]]></category>
		<category><![CDATA[moves]]></category>
		<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[rise]]></category>
		<category><![CDATA[shares]]></category>
		<category><![CDATA[testing]]></category>
		<category><![CDATA[Therapeutics]]></category>
		<category><![CDATA[Viking]]></category>
		<category><![CDATA[weightloss]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=9953</guid>

					<description><![CDATA[Shares of Viking Therapeutics rose 16% in premarket trading on Thursday after the biotech company announced a day earlier plans to advance its experimental weight-loss injection into a complicated testing phase sooner than expected. This brings the San Diego-based company one step closer to entering the extremely popular GLP-1 market, which analysts say is developing [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div id="RegularArticle-ArticleBody-5" data-module="ArticleBody" data-test="articleBody-2" data-analytics="RegularArticle-articleBody-5-2"><span class="HighlightShare-hidden" style="top:0;left:0"></span></p>
<div class="group">
<p>Shares of <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-1">Viking Therapeutics<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>    rose 16% in premarket trading on Thursday after the biotech company announced a day earlier <a href="https://www.prnewswire.com/news-releases/viking-therapeutics-reports-second-quarter-2024-financial-results-and-provides-corporate-update-302205767.html" target="_blank" rel="noopener">plans</a> to advance its experimental weight-loss injection into a complicated testing phase sooner than expected. </p>
<p>This brings the San Diego-based company one step closer to entering the extremely popular GLP-1 market, which analysts say is developing right into a <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/weight-loss-drug-forecasts-jump-150-billion-supply-grows-2024-05-28/" target="_blank" rel="noopener">150 billion dollar market</a> until the top of the last decade. </p>
<p>Viking is considered one of several small and enormous pharmaceutical corporations that need to compete on this area <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-6">Novo Nordisk<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>    And <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-7">Eli Lilly<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>whose demand for GLP-1 antibodies for weight reduction and diabetes has skyrocketed within the last two years. </p>
<p>Shares of Novo Nordisk and Eli Lilly fell about 2 percent in premarket trading on Thursday. </p>
<p>Viking had previously stated that the corporate expected to start one other interim study of its weekly injection, called VK2735, after the corporate reported positive results from one other phase two study in late February. </p>
<p>But after the corporate received written feedback from the U.S. Food and Drug Administration (FDA), it decided to maneuver the injection directly right into a Phase 3 trial, CEO Brian Lian said during a conference call on Wednesday. </p>
<p>Lian said the corporate is preparing to satisfy with the FDA within the fourth quarter to debate the design and timing of this Phase 3 trial, with plans to initiate the study afterward.</p>
<p>The decision will likely shorten Viking&#39;s development timeline for the injection by a 12 months, BTIG analyst Justin Zelin said in a note Wednesday. Currently, analysts expect the drug to hit the market in 2029, Zelin said. </p>
<p>During the decision, Lian added that Viking plans to check VK2735 as a monthly injection in a future study, which could make the treatment a more convenient option than Eli Lilly&#39;s Zepbound and Novo Nordisk&#39;s Wegovy, each of that are taken once every week.</p>
<p>Viking Therapeutics&#39; drug promotes weight reduction by targeting GLP-1 and one other hormone called GIP, the identical hormones targeted by Eli Lilly&#39;s Zepbound and its diabetes counterpart Mounjaro.</p>
<p>Patients who received the Viking injection weekly in a Phase 2 study lost as much as 14.7 percent of their body weight after 13 weeks, or 13.1 percent in comparison with placebo. </p>
<p>Viking can be developing an oral version of VK2735. This pill resulted in a weight reduction of three.3% in comparison with a placebo in an early study. </p>
</div>
</div>
<p><em>image credit : www.cnbc.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://image.cnbcfm.com/api/v1/image/107378853-1709040141961-gettyimages-1665778558-img_5416-1.jpeg?v=1721911495&#038;w=1920&#038;h=1080" medium="image"></media:content>
	</item>
	</channel>
</rss>
